Corvus Pharmaceuticals Files 8-K on Financials
Ticker: CRVS · Form: 8-K · Filed: May 6, 2024 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, filing
Related Tickers: CRVS
TL;DR
CRVS filed an 8-K on financials, check for updates.
AI Summary
Corvus Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Corvus Pharmaceuticals' financial condition, which is crucial for investors to assess the company's stability and performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial condition and exhibits, with no immediate material adverse events indicated.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- May 6, 2024 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
This 8-K was filed on May 6, 2024.
What is Corvus Pharmaceuticals' principal executive office address?
The principal executive offices are located at 863 Mitten Road, Suite 102, Burlingame, California 94010.
What is the company's telephone number?
The company's telephone number is (650) 900-4520.
What is the SIC code for Corvus Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Corvus Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-06 16:01:14
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market I
Filing Documents
- f8k_050624.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 49KB
- fig1.jpg (GRAPHIC) — 41KB
- 0001171843-24-002569.txt ( ) — 328KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_050624_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 6, 2024, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the three months ended March 31, 2024 and its financial position as of March 31, 2024, and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated May 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corvus Pharmaceuticals, Inc. Date: May 6, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer